Proteon Therapeutics (NASDAQ:PRTO) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
This is a breakdown of recent recommendations for Proteon Therapeutics and BioCardia, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility & Risk
Proteon Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.
Institutional & Insider Ownership
25.6% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of BioCardia shares are owned by institutional investors. 45.7% of Proteon Therapeutics shares are owned by company insiders. Comparatively, 26.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Proteon Therapeutics and BioCardia’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Proteon Therapeutics||N/A||N/A||-$20.73 million||($1.15)||-0.25|
BioCardia has higher revenue and earnings than Proteon Therapeutics.
This table compares Proteon Therapeutics and BioCardia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Proteon Therapeutics beats BioCardia on 6 of the 11 factors compared between the two stocks.
About Proteon Therapeutics
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.